Title

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

Inventors

Keith Sandoon Bahjat
Helena Maria Hoen
Yoshinobu Koguchi, Robert W Franz Cancer Center, Earle A Chiles Research Institute, Portland, OR, USAFollow
Alan J. Korman

Document Type

Patent

File Date

4-20-2021

Keywords

oregon; portland

Abstract

Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.

Clinical Institute

Cancer

Department

Oncology

Location

Portland, OR

Assignee

BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ); Providence Health & Services (Portland, OR)

Family ID

55487083

Tech ID

US 20180246113 A1

Recommended Citation

Bahjat, Keith Sandoon; Hoen, Helena Maria; Koguchi, Yoshinobu; and Korman, Alan J., "CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy" (2021). Technology Transfer - Patents. 60.
https://digitalcommons.providence.org/technologytransfer/60